{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T21:33:59Z","timestamp":1787693639240,"version":"build-2784847793"},"reference-count":24,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.revmed.2013.04.007","type":"journal-article","created":{"date-parts":[[2013,6,4]],"date-time":"2013-06-04T15:04:22Z","timestamp":1370358262000},"page":"493-496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacit\u00e9 du rituximab dans un cas de syndrome de Lambert-Eaton non paran\u00e9oplasique s\u00e9ron\u00e9gatif"],"prefix":"10.1016","volume":"34","author":[{"given":"E.","family":"Boutin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Romeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Pouget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Franques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2013.04.007_bib0005","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","article-title":"Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies","volume":"10","author":"Titulaer","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.revmed.2013.04.007_bib0010","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0035-3787(04)71002-4","article-title":"Dosage et sp\u00e9cificit\u00e9 d\u2019autoanticorps anti-canaux calcium dans le syndrome myasth\u00e9nique de Lambert-Eaton","volume":"160","author":"Martin-Moutot","year":"2004","journal-title":"Rev Neurol"},{"key":"10.1016\/j.revmed.2013.04.007_bib0015","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.revmed.2011.04.003","article-title":"Canalopathies auto-immunes","volume":"32","author":"Michaud","year":"2011","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2013.04.007_bib0020","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1200\/JCO.2010.32.0440","article-title":"Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS","volume":"29","author":"Titulaer","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2013.04.007_bib0025","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.revmed.2010.09.007","article-title":"Les syndromes neurologiques paran\u00e9oplasiques","volume":"32","author":"Didelot","year":"2011","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2013.04.007_bib0030","first-page":"808","article-title":"Lambert-Eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy","volume":"2011","author":"Gilhus","year":"2011","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.revmed.2013.04.007_bib0035","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/jnnp.70.2.212","article-title":"Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer","volume":"70","author":"Maddison","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.revmed.2013.04.007_bib0040","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s00415-003-1063-7","article-title":"The epidemiology of myasthenia gravis. Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland","volume":"250","author":"Wirtz","year":"2003","journal-title":"J Neurol"},{"key":"10.1016\/j.revmed.2013.04.007_bib0045","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1212\/WNL.40.10.1552","article-title":"Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma","volume":"40","author":"Chalk","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.revmed.2013.04.007_bib0050","doi-asserted-by":"crossref","first-page":"19e3","DOI":"10.1111\/j.1468-1331.2010.03220.x","article-title":"Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force","volume":"18","author":"Titulaer","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.revmed.2013.04.007_bib0055","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1212\/01.WNL.0000037485.56217.5F","article-title":"Seronegative Lambert-Eaton myasthenic syndrome","volume":"59","author":"Nakao","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.revmed.2013.04.007_bib0060","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/mus.21422","article-title":"3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS","volume":"40","author":"Oh","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.revmed.2013.04.007_bib0065","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.54.3.603","article-title":"A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome","volume":"54","author":"Sanders","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.revmed.2013.04.007_bib0070","first-page":"CD003279","article-title":"Treatment for Lambert-Eaton myasthenic syndrome","author":"Keogh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.revmed.2013.04.007_bib0075","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.revmed.2011.07.001","article-title":"Rituximab et traitement des vascularites associ\u00e9es aux anticorps anticytoplasme des polynucl\u00e9aires neutrophiles (ANCA)","volume":"32","author":"Guillevin","year":"2011","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2013.04.007_bib0080","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-cd20\u00a0monoclonal antibody: history and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.revmed.2013.04.007_bib0085","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.revmed.2004.12.013","article-title":"Rituximab: a original biotherapy in auto-immune disorders","volume":"26","author":"Sibilia","year":"2005","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2013.04.007_bib0090","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/mus.21315","article-title":"Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction","volume":"40","author":"Pellkofer","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.revmed.2013.04.007_bib0095","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.2009.197632","article-title":"The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"82","author":"Maddison","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.revmed.2013.04.007_bib0100","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/rheumatology\/ker176","article-title":"Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus: a prospective pilot study","volume":"50","author":"Chen","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.revmed.2013.04.007_bib0105","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3324\/haematol.11709","article-title":"Activity and safety profile of lowdose rituximab for the treatment of autoimmune cytopenias in adults","volume":"92","author":"Provan","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2013.04.007_bib0110","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.revmed.2013.04.007_bib0115","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/1352458511432896","article-title":"Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success","volume":"18","author":"Greenberg","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.revmed.2013.04.007_bib0120","doi-asserted-by":"crossref","first-page":"w13073","DOI":"10.4414\/smw.2010.13073","article-title":"Swiss consensus statement: recommendations for optimising re-treatment with MabThera (rituximab) in rheumatoid arthritis","volume":"140","author":"Dudler","year":"2010","journal-title":"Swiss Med Wkly"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866313005043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866313005043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:31:18Z","timestamp":1759336278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866313005043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0248866313005043"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2013.04.007","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacit\u00e9 du rituximab dans un cas de syndrome de Lambert-Eaton non paran\u00e9oplasique s\u00e9ron\u00e9gatif","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2013.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Soci\u00e9t\u00e9 nationale fran\u00e7aise de m\u00e9decine interne (SNFMI). Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}